Munich Reinsurance Co Stock Corp in Munich Boosts Stock Position in Quest Diagnostics Incorporated $DGX

Munich Reinsurance Co Stock Corp in Munich raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 72.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,324 shares of the medical research company’s stock after acquiring an additional 10,188 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Quest Diagnostics were worth $5,155,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Quattro Advisors LLC purchased a new position in shares of Quest Diagnostics in the 4th quarter valued at $25,000. Key Financial Inc raised its stake in Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after acquiring an additional 121 shares in the last quarter. DV Equities LLC purchased a new stake in Quest Diagnostics in the fourth quarter valued at $27,000. Sittner & Nelson LLC acquired a new position in Quest Diagnostics in the fourth quarter valued at $29,000. Finally, Ancora Advisors LLC acquired a new position in Quest Diagnostics in the second quarter valued at $29,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insider Activity

In other news, CEO J. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the sale, the chief executive officer owned 122,423 shares in the company, valued at $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 34,277 shares of company stock valued at $8,316,493. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $236.75 on Friday. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $247.19. The stock has a market capitalization of $26.13 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 2.19 and a beta of 0.55. The company has a 50-day simple moving average of $227.64 and a 200-day simple moving average of $208.31. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. Quest Diagnostics’s payout ratio is presently 36.52%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DGX. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. UBS Group upped their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Mizuho raised their price target on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, August 12th. Finally, Robert W. Baird increased their price objective on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $235.31.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.